Clinical experience with infliximab biosimilar in psoriasis

Abstract

biosimilar medicines are biological medicine that have been developed to be highly similar and clinically equivalent to an existing biological medicine. Just as patent expiry for conventional drugs has led to the marketing of generic versions, the expiry of data protection and patents for original biologics has prompted development of biosimilars.

This article is protected by copyright. All rights reserved.

http://ift.tt/2t5YlQl